


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) Compounds of the formula (I):



in which:

- G represents a bond or a divalent radical chosen from the groups g1, g2 and g3 below:



g1

;



g2

;



g3

;

- R¹ is chosen from hydrogen and an alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl or alkoxy carbonyl radical;
- R² and R³, which may be identical or different, are chosen, independently of each other, from a hydrogen atom, an alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl radical and a radical -NRR';
- R⁴, R⁵ and R⁶, which may be identical or different, are chosen, independently of each other, from a hydrogen atom and an alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl radical;
- R and R', which may be identical or different, represent, independently of each other, a hydrogen atom or a radical chosen from alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl; or together form, with the nitrogen atom that

bears them, a heterocycle, or together form the double bond of an alken-1-yl radical;

- Y represents an oxygen or sulfur atom; and
- Z represents -NH- or an oxygen atom;

~~the possible or a geometrical and/or optical isomer, epimer, and various tautomeric forms, and possible oxidized forms, especially a tautomer, amine oxide, thereof, the solvates, and the hydrates, of these compounds;~~

~~and also the possible pharmaceutically acceptable salt thereof with an acid or a base, or the pharmaceutically acceptable prodrug of these compounds thereof.~~

2. (Currently Amended) Compounds according to Claim 1, in which the radical R² represents hydrogen;
~~the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and possible oxidized forms, especially amine oxides, thereof, the solvates and the hydrates of these compounds;~~

~~and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or the pharmaceutically acceptable prodrugs of these compounds or a geometrical or optical isomer, epimer, tautomer, amine oxide solvate, hydrate, pharmaceutically acceptable salt with an acid or a base, or pharmaceutically acceptable prodrug thereof.~~

3. (Currently Amended) Compounds according to Claim 1, in which the radical R³ represents hydrogen;
~~the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and possible oxidized forms, especially amine oxides, thereof, the solvates and the hydrates of these compounds;~~

~~and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or the pharmaceutically acceptable prodrugs of these compounds or a geometrical or optical isomer, epimer, tautomer, amine oxide solvate, hydrate, pharmaceutically acceptable salt with an acid or a base, or pharmaceutically acceptable prodrug thereof.~~

4. (Currently Amended) Compounds according to Claim 1, in which the radicals R⁴ and R⁵, independently of each other, represent an alkyl radical,

~~the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and optional oxidized forms, especially amine oxides, thereof, and the solvates and hydrates of these compounds;~~

~~and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or the pharmaceutically acceptable prodrugs of these compounds or a geometrical or optical isomer, epimer, tautomer, amine oxide solvate, hydrate, pharmaceutically acceptable salt with an acid or a base, or pharmaceutically acceptable prodrug thereof.~~

5. (Currently Amended) Compounds according to Claim 1, in which the radical R⁶ represents an aryl or heteroaryl radical;

~~the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and optional oxidized forms, especially amine oxides, thereof, and the solvates and hydrates of these compounds;~~

~~and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or the pharmaceutically acceptable prodrugs of these compounds or a geometrical or optical isomer, epimer, tautomer, amine oxide solvate, hydrate, pharmaceutically acceptable salt with an acid or a base, or pharmaceutically acceptable prodrug thereof.~~

6. (Currently Amended) Compounds according to Claim 1, in which in which the thiazolyl radical is branched in position 3 or in position 4 of the piperidine nucleus,

~~the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and optional oxidized forms, especially amine oxides, thereof, and the solvates and hydrates of these compounds;~~

~~and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or the pharmaceutically acceptable prodrugs of these compounds or a geometrical or optical isomer,~~

epimer, tautomer, amine oxide solvate, hydrate, pharmaceutically acceptable salt with an acid or a base, or pharmaceutically acceptable prodrug thereof.

7. (Currently Amended) Compounds according to Claim 1, in which the thiazolyl radical is branched in position 4 of the piperidine nucleus,

~~the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and optional oxidized forms, especially amine oxides, thereof, and the solvates and hydrates of these compounds;~~

~~and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or the pharmaceutically acceptable prodrugs of these compounds or a geometrical or optical isomer, epimer, tautomer, amine oxide solvate, hydrate, pharmaceutically acceptable salt with an acid or a base, or pharmaceutically acceptable prodrug thereof.~~

8. (Currently Amended) Compounds according to Claim 1, in which G represents the radical g1,

~~the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and optional oxidized forms, especially amine oxides, thereof, and the solvates and hydrates of these compounds;~~

~~and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or the pharmaceutically acceptable prodrugs of these compounds or a geometrical or optical isomer, epimer, tautomer, amine oxide solvate, hydrate, pharmaceutically acceptable salt with an acid or a base, or pharmaceutically acceptable prodrug thereof.~~

9. (Currently Amended) Compounds according to Claim 1, in which G represents the radical g1 and Y represents an oxygen atom,

~~the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and optional oxidized forms, especially amine oxides, thereof, and the solvates and hydrates of these compounds;~~

~~and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or~~

the pharmaceutically acceptable prodrugs of these compounds or a geometrical or optical isomer, epimer, tautomer, amine oxide solvate, hydrate, pharmaceutically acceptable salt with an acid or a base, or pharmaceutically acceptable prodrug thereof.

10. (Currently Amended) Compounds according to Claim 1, in which the radicals R^2 and R^3 each represent a hydrogen atom, the radicals R^4 and R^5 represent, independently of each other, an alkyl radical, the radical R^6 represents an aryl or heteroaryl radical, the thiazolyl radical is branched in position 4 of the piperidine nucleus, and G represents the radical g1 in which Y represents an oxygen atom,

~~the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and optional oxidized forms, especially amine oxides, thereof, and the solvates and hydrates of these compounds;~~

~~and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or the pharmaceutically acceptable prodrugs of these compounds or a geometrical or optical isomer, epimer, tautomer, amine oxide solvate, hydrate, pharmaceutically acceptable salt with an acid or a base, or pharmaceutically acceptable prodrug thereof~~

11. (Currently Amended) Compounds according to Claim 1, in which R^1 represents an aryl radical, especially phenyl, substituted by one or more aryl and/or alkyl radicals

~~the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and optional oxidized forms, especially amine oxides, thereof, and the solvates and hydrates of these compounds;~~

~~and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or the pharmaceutically acceptable prodrugs of these compounds or a geometrical or optical isomer, epimer, tautomer, amine oxide solvate, hydrate, pharmaceutically acceptable salt with an acid or a base, or pharmaceutically acceptable prodrug thereof.~~

12. (Currently Amended) Compounds according to Claim 1, in which R^1 represents a biphenyl radical, optionally substituted by one or more alkyl radicals, preferably methyl, ethyl or

propyl, and/or with a perhaloalkyl or perhaloalkoxy radical,

~~the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and optional oxidized forms, especially amine oxides, thereof, and the solvates and hydrates of these compounds;~~

~~and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or the pharmaceutically acceptable prodrugs of these compounds or a geometrical or optical isomer, epimer, tautomer, amine oxide solvate, hydrate, pharmaceutically acceptable salt with an acid or a base, or pharmaceutically acceptable prodrug thereof.~~

13. (Currently Amended) Compounds according to Claim 1, in which G represents the radical g1, with Y representing an oxygen atom, R¹ represents a biphenyl radical, optionally substituted by one or more alkyl radicals, preferably methyl, ethyl or propyl, and/or a trifluoromethyl or trifluoromethoxy radical, the other substituents being as defined above,

~~the possible geometrical and/or optical isomers, epimers and various tautomeric forms, and optional oxidized forms, especially amine oxides, thereof, and the solvates and hydrates of these compounds;~~

~~and also the possible pharmaceutically acceptable salts thereof with an acid or a base, or the pharmaceutically acceptable prodrugs of these compounds or a geometrical or optical isomer, epimer, tautomer, amine oxide solvate, hydrate, pharmaceutically acceptable salt with an acid or a base, or pharmaceutically acceptable prodrug thereof.~~


14. (Currently Amended) Compounds according to Claim 1, ~~chosen from which is:~~

- {4-[4-(1,5-dimethyl-4-phenyl-1*H*-imidazol-2-yl)thiazol-2-yl]piperid-1-yl}(4'-trifluoromethylbiphenyl-2-yl)methanone;
- {4-[4-(1-ethyl-5-methyl-4-phenyl-1*H*-imidazol-2-yl)thiazol-2-yl]piperid-1-yl}(4'-trifluoromethylbiphenyl-2-yl)methanone;
- {3-[4-(1-ethyl-5-methyl-4-phenyl-1*H*-imidazol-2-yl)thiazol-2-yl]piperid-1-yl}(4'-trifluoromethylbiphenyl-2-yl)methanone;


- {4-[4-(1-ethyl-5-methyl-4-phenyl-1*H*-imidazol-2-yl)thiazol-2-yl]piperid-1-yl}(6-methyl-4'-trifluoromethoxybiphenyl-2-yl)methanone;
- {4-[4-(1-ethyl-5-methyl-4-(pyrid-3-yl)-1*H*-imidazol-2-yl)thiazol-2-yl]piperid-1-yl}(4'-trifluoromethylbiphenyl-2-yl)methanone;
- {4-[4-(1-ethyl-5-methyl-4-(pyrid-2-yl)-1*H*-imidazol-2-yl)thiazol-2-yl]piperid-1-yl}(4'-trifluoromethylbiphenyl-2-yl)methanone; and
- {4-[4-(1-ethyl-5-methyl-4-(pyrid-2-yl)-1*H*-imidazol-2-yl)thiazol-2-yl]piperid-1-yl}(6-methyl-4'-trifluoromethoxybiphenyl-2-yl)methanone;

the optical isomers thereof, oxidized forms, solvates and hydrates of these compounds; and also the possible pharmaceutically acceptable salts thereof with an acid, or the pharmaceutically acceptable prodrugs of these compounds or a geometrical or optical isomer, epimer, tautomer, amine oxide solvate, hydrate, pharmaceutically acceptable salt with an acid or a base, or pharmaceutically acceptable prodrug thereof.

15. (Currently Amended) A process ~~Process~~ for the preparation of a compound according to Claim 1, ~~characterized in that~~ comprising reacting a compound of the formula (II):




in which T represents a labile protecting group, and ~~R² is as defined in Claim 1,~~
~~is reacted with ethyl R³-bromopyruvate, in a polar solvent, in the presence of an excess of~~
base, preferably an organic base, at a suitable temperature, for a period ranging from 1 to 40 hours
and preferably between 4 and 18 hours,
so as to form ~~the~~ a thiazolyl ring and ~~give the~~ a compound of the formula (III):




in which T is as defined above, and R² and R³ are as defined in Claim 1,

which saponifying the compound of the formula (III) is then saponified with a base, ~~of with an~~ alkali metal or alkaline-earth metal hydroxide ~~type base~~, in polar medium, at room temperature, for a period ~~ranging from~~ 1 to 12 hours, so as to form the salt of the formula (IV):




in which T, R² and R³ are as defined above, and M⁺ represents the alkali metal or alkaline-earth metal cation derived from the base that is ~~useful used~~ for the saponification reaction,

which hydrolyzing the compound of the formula (IV) is next hydrolysed and then ~~or esterified~~ to a compound of the formula (V):




in which R², R³ and T are as defined above,

which converting the compound of the formula (V) is then converted to a corresponding amide of the formula (VI):




in which R^2 , R^3 , R^4 , R^5 , R^6 and T are as defined above,
via the action of an amine of the formula (VIa):



in which R^4 , R^5 and R^6 are as defined above,


in the presence of a base, preferably an organic base, and a catalyst, in a polar aprotic solvent, at room temperature, for a period possibly ranging from 1 to 50 hours,

the compound of the formula (VI) then being used in a reaction for deprotection deprotecting of the amine function of the piperidine ring of VI, via the action of an organic or mineral acid, in dichloromethane or dioxane medium, at room temperature, for a period ranging from a few minutes to several hours, to give the compound of the formula (VII):



in which R^2 , R^3 , R^4 , R^5 and R^6 are as defined above,


which subjecting said compound VIII is then subjected to the action of a compound chosen from:



in which X represents a halogen atom, preferably chlorine, R^1 , Y and Z being as defined in Claim 1,

in the presence of a base, preferably an organic base, and a catalyst, in a polar aprotic

solvent, at room temperature, for a period possibly ranging from 1 to 50 hours,
to give the compound of the formula (VIII):



in which G, R¹, R², R³, R⁴, R⁵ and R⁶ are as defined above,

which is finally subjected and subjecting VIII to a cyclization reaction (formation of to form the imidazole ring), in the presence of a cyclizing agent, such as ammonium trifluoroacetate, also acting as a solvent, at a suitable temperature, for example in the region of 150°C, for a period generally of between 5 and 15 minutes,

to give the compound of the formula (I) as defined in Claim 1.

16. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ composition comprising a pharmaceutically effective amount of a compound of the formula (I) according to Claim 1, in combination with one or more pharmaceutically acceptable vehicles.

17. (Currently Amended) Use of a compound of the formula (I) according to Claim 1, for the preparation of a medicament ~~A method~~ for the treatment of diabetes-related hypertriglyceridaemia, hypercholesterolaemia, and dyslipidaemia, and also ~~or~~ for the prevention and/or treatment of obesity, comprising administering to a host in need thereof an effective amount of a compound of claim 1.